Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) Patents (Class 424/184.1)
  • Patent number: 11324739
    Abstract: Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production arlinee also described.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 10, 2022
    Assignee: Jiangsu Yahong Meditech Co., Ltd.
    Inventors: Ke Pan, Peng Huang, Qiang Li
  • Patent number: 11311616
    Abstract: The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 26, 2022
    Assignee: Intervet Inc.
    Inventor: Ian Tarpey
  • Patent number: 11312953
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 26, 2022
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • Patent number: 11292817
    Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: April 5, 2022
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Michael Niederweis, Mikhail Pavlenok
  • Patent number: 11278624
    Abstract: According to the invention there is provided inter alia an aqueous liquid pharmaceutical formulation comprising insulin or an insulin analogue, ionic zinc, a chelating agent and polysorbate 80.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 22, 2022
    Assignee: ARECOR LIMITED
    Inventors: David Gerring, Leon Zakrzewski, Jan Jezek, Sarah Howell
  • Patent number: 11260067
    Abstract: The present invention relates to a nutritional composition comprising at least two human milk oligosaccharides, for use to decrease the concentration of detrimental proteolytic metabolites (e.g. branched short chain fatty acids) in the digestive tract in an infant or a young child.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: March 1, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Norbert Sprenger, Florence Rochat, Laurent Favre
  • Patent number: 11253466
    Abstract: The present description relates to a skin ointment or topical composition for skin rejuvenation and/or repair. The composition generally comprises: a biocompatible mixture of probiotics (e.g., probiotic yeast and/or bacteria); admixed with one or more of: exfoliating agents, mud and/or clay, blood circulation promoting agent, and nutrients. Methods, uses and kits relating to same are also described.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: February 22, 2022
    Assignee: DAVINCIA INC.
    Inventor: Nathalie Forget
  • Patent number: 11242386
    Abstract: A chimeric antigen receptor (CAR) that binds to CEACAM6, an epitope or fragment thereof, or a variant thereof.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: February 8, 2022
    Inventors: Heman Lap Man Chao, Wah Yau Wong, Baomin Tian, Lakshmi Krishnan, Jamshid Tanha, Marni Diane Uger
  • Patent number: 11225502
    Abstract: This disclosure concerns a method for making a hybrid organic/inorganic material having an architecture. The method includes combining a peptoid comprising a sequence of N-substituted glycine residues and an inorganic material or inorganic material precursor to form a hybrid organic/inorganic material comprising the peptoid and the inorganic material, the hybrid organic/inorganic material having an architecture based at least in part on the peptoid sequence. The hybrid organic/inorganic materials include a cluster of nanoparticles of an inorganic material and peptoids, the cluster formed by random attachment of nanoparticles to one another by peptoid-peptoid and peptoid-nanoparticle surface interactions, wherein the hybrid material has an architecture based at least in part on the peptoid sequence.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: January 18, 2022
    Assignee: Battelle Memorial Institute
    Inventor: Chun-Long Chen
  • Patent number: 11219679
    Abstract: The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: January 11, 2022
    Assignee: VAXIION THERAPEUTICS, LLC
    Inventor: Matthew J. Giacalone
  • Patent number: 11213590
    Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: January 4, 2022
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rajesh R. Shinde, Rossitza G. Alargova, Patrick Lim Soo, Beata Sweryda-Krawiec, Leila Alland, Christopher Sears
  • Patent number: 11207405
    Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, selected from a cell, protein, peptide, antibody or antigen binding fragment thereof, directed against CTLA-4, PD-1, PD-L1 and combinations thereof, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: December 28, 2021
    Inventors: Charles Akle, Laura Rosa Brunet
  • Patent number: 11203740
    Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising performing a depth filtration of a starting material previously obtained from cells producing rAAV particles comprising a cell lysate and/or a culture supernatant, followed by a first step of anion-exchange chromatography, a second step of anion-exchange chromatography and a final step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: December 21, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CHU NANTES, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
    Inventor: Nicole Brument
  • Patent number: 11197921
    Abstract: The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and/or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: December 14, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jitin Bajaj, Michael Albert Winters, Emily Wen, Jian He
  • Patent number: 11193114
    Abstract: The invention describes new peptides containing epitopes recognized by CD4+ natural killer T (NKT) cells for increasing activity for use in infectious diseases, autoimmune diseases, immune reaction to administration of allofactors, allergic diseases, therapy of tumors, prevention of graft rejection and prevention of immunization against viral proteins used in gene therapy or gene vaccination.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: December 7, 2021
    Assignee: IMNATE SARL
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 11185562
    Abstract: Compositions for methods of preventing or reducing pathogenic bacterial growth, proliferation, and/or colonization are described containing one or more types of non-pathogenic bacteria to be introduced into the gastrointestinal tract and effectively compete with pathogenic bacteria for monomeric or polymeric carbohydrate nutrients, and/or amino acid nutrients, and/or vitamin nutrients.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: November 30, 2021
    Assignee: Seres Therapeutics, Inc.
    Inventors: David N. Cook, Han Zhang, Anthony Mario D'Onofrio, David Arthur Berry, Mary-Jane Lombardo McKenzie, John Grant Aunins, Gregory McKenzie, Toshiro K. Ohsumi
  • Patent number: 11161874
    Abstract: The present invention relates to a novel tumor-specific polypeptide and use thereof. In particular, the present invention relates to a tumor-specific polypeptide having high affinity for HLA-A0201 and having cytotoxic T lymphocyte inducing ability, and its use for diagnosing, preventing and treating diseases (especially cancer) associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: November 2, 2021
    Assignee: GENOIMMUNE THERAPEUTICS CO., LTD.
    Inventors: Yong Hou, Shuntao Luo, Ting An, Xiumei Lin, Bo Li, Guanglei Li
  • Patent number: 11160832
    Abstract: Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: November 2, 2021
    Assignees: The Children's Mercy Hospital, The University of Kansas
    Inventors: Amara Seng, Ryan Fischer, Thomas Yankee, Mary Markiewicz, John Szarejko
  • Patent number: 11160871
    Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: November 2, 2021
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Richard Wooster, Kerry Whalen, Patrick Rosaire Bazinet, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino, Beata Sweryda-Krawiec, Rajesh R. Shinde
  • Patent number: 11155585
    Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 26, 2021
    Assignee: INTERVACC AB
    Inventors: Bengt Guss, Lars Frykberg, Margareta Flock, Jan-Ingmar Flock, Karl Olov Zachrisson
  • Patent number: 11147878
    Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: October 19, 2021
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Patent number: 11147860
    Abstract: The present invention relates to a liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor. A liquid formulation containing botulinum toxin and stabilizing agent according to the present invention can be easily stored and distributed. It was proved a significant effect on the stabilization of botulinum toxin under suitable conditions according to the temperature and pH of the human body. Thus, it is expected that the pharmaceutical composition of the present invention will greatly contribute to the safe and convenient medical use of botulinum toxin.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: October 19, 2021
    Assignee: Hugel Inc.
    Inventors: Chee Gun Lee, Ji Hyun Oum
  • Patent number: 11136369
    Abstract: This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: October 5, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: H. Trent Spencer, Christopher B. Doering, Brantley R. Herrin, Max Dale Cooper
  • Patent number: 11136579
    Abstract: The present invention relates to antisense oligonucleotides for modulating the activity of PRDM15 and use thereof in the treatment of cancer. In particular, said antisense oligonucleotides are capable of inducing the skipping of an exon of a PRDM15 mRNA. The present invention also relates to a method for determining prognosis in a patient with cancer, or selecting a therapeutic strategy for a patient with cancer, by assessing the level of PRDM15 nucleic acid, protein or activity in a sample.
    Type: Grant
    Filed: September 4, 2017
    Date of Patent: October 5, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Ernesto Guccione, Keng Boon Dave Wee
  • Patent number: 11135279
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 5, 2021
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Patent number: 11135285
    Abstract: The invention pertains to a vaccine comprising in combination non-replicating immunogens of Erysipelothrix rhusiopathiae, porcine parvo virus, Leptospira interrogans and live attenuated PRRS virus, and a pharmaceutically acceptable carrier, for use in a method for prophylactic treatment of a swine against an infection with Erysipelothrix rhusiopathiae, porcine parvo virus, Leptospira interrogans and PRRS virus, wherein the vaccine is administered in a single dose with regard to the treatment against an infection with PRRS virus.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: October 5, 2021
    Assignee: Intervet Inc.
    Inventors: Erwin Born van den, Antonius Arnoldus Christiaan Jacobs, Melanie Sno
  • Patent number: 11136368
    Abstract: Blocking peptides that inhibit FAK or NANOG binding to Cx26, and a method of treating cancer by administering these blocking peptides to a subject in need thereof are described.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: October 5, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Justin D. Lathia, Ofer Reizes
  • Patent number: 11136358
    Abstract: The present invention relates to a plasmid-based CTX phage replication system and Vibrio cholerae strain that can be infected by CTX phage and can be used for cholera toxin production. More particularly, the present invention provides a Vibrio cholera variant strain, which expresses a toxT protein in which tyrosine at position 139 is substituted by phenylalanine through the point mutation of a toxT gene using a plasmid-based CTX phage replication system, and is used as a receptor strain which can improve CTX phage infection efficiency and allows a plurality of CTX prophages to simultaneously infect the strain and to be inserted into the chromosome thereof, which the consequent provision of the effect of increasing the production yield of a cholera toxin.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: October 5, 2021
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
    Inventors: Dong Wook Kim, Eun Jin Kim, Hyun Jin Yu
  • Patent number: 11123398
    Abstract: The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with a cytotoxic chemotherapeutic agent that inhibits immune tolerance, wherein the chemotherapeutic agent is administered at a sub-cytotoxic dose.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: September 21, 2021
    Assignee: LYTIX BIOPHARMA AS
    Inventors: Liv Marie Eike, Ketil Camilio, Baldur Sveinbjornsson, Oystein Rekdal, John Sigurd Mjoen Svendsen
  • Patent number: 11118165
    Abstract: The present invention provides a cytokine-based culture method for ex vivo expansion of NK cells from postembryonic hematopoietic stem cells into a fully closed, large-scale, cell culture bioprocess. We optimized enrichment of CD34+ cells followed by efficient expansion in gas-permeable cell culture bags. Thereafter, expanded CD34+ cells could be reproducibly amplified and differentiated into CD56+CD3? NK cell products with a mean expansion of more than 2,000 fold and a purity of >90%. Also provided are collections of cultured cells having specific properties.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: September 14, 2021
    Assignee: GLYCOSTEM THERAPEUTICS B.V.
    Inventors: Jan Spanholtz, Harmen Dolstra
  • Patent number: 11116831
    Abstract: Provided is a recombinant P particle formed from a norovirus capsid P protein of a chimeric A?1-m peptide (m being an integer ranging from 6 to 15), wherein the recombinant P particles form an ordered and repetitive antigen array. Also provided are a nucleotide sequence encoding the recombinant P particle, a pharmaceutical composition comprising same and a use thereof for preparing a medicament for treating or preventing Alzheimer's disease. Also provided is a method for preparing the recombinant P particle.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 14, 2021
    Assignees: Changchun BCHT Biotechnology Co., Jilin University
    Inventors: Wei Kong, Hui Wu, Chunlai Jiang, Xianghui Yu, Lu Fu, Yingnan Li
  • Patent number: 11111277
    Abstract: Provided herein are compositions related to vaccines, e.g., influenza vaccines, including, peptide based vaccines, nucleic acid based vaccines, recombinant virus based vaccines, antibody based vaccines, and virus based vaccines. Also provided herein are methods related to vaccines, e.g., influenza vaccines, including methods of identifying epitopes for the vaccines, producing, formulating, and administering the vaccines.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 7, 2021
    Assignees: InvVax, Inc., The Regents of the University of California
    Inventors: Arthur Young, Ren Sun, Nicholas C. Wu
  • Patent number: 11103561
    Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: August 31, 2021
    Assignee: Hamlet Pharma AB
    Inventors: Catharina Svanborg, Manoj Puthia, Chin Shing Ho
  • Patent number: 11103466
    Abstract: The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition. Some embodiments of the present disclosure relate to an immunogenic composition operable as a treatment of cancer in a subject having a subject weight, the immunogenic composition including; an immunoactive tissue extract comprising a protein composition, wherein the immunogenic composition has a final concentration of the protein composition of about 6 mg to about 10 mg of the protein composition per kg of the subject weight; an immune response activator comprising a BCG solution, wherein the immunogenic composition has a final concentration of the immune response activator of about 0.525 to about 0.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 31, 2021
    Assignee: JACINTO CONVIT WORLD ORGANIZATION INC.
    Inventor: Jacinto Convit
  • Patent number: 11096988
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: August 24, 2021
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Ryan Swanson, Michael Kornacker, Mark F. Maurer, Joseph L. Kuijper
  • Patent number: 11096987
    Abstract: The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating autoimmune disease using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: August 24, 2021
    Assignee: BIOINCEPT, LLC
    Inventor: Eytan R. Barnea
  • Patent number: 11090375
    Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: August 17, 2021
    Assignee: Pfizer Inc.
    Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
  • Patent number: 11078237
    Abstract: This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: August 3, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Michael Franti, Anders Lilja, Rebecca Loomis, Peter W. Mason
  • Patent number: 11058744
    Abstract: The present invention relates to a composition for treating prostate cancer and, more specifically, to a composition for treating prostate cancer, which contains a peptide derived from telomerase and is effective in inhibiting growth and metastasis of prostate cancer cells. In addition, the present invention provides a composition and method for treating prostate cancer, wherein, when prostate cancer is treated, docetaxel and the peptide derived from telomerase are co-administered, thereby having a synergetic therapeutic effect compared with administration alone. Particularly, the present invention provides a treatment method useful for patients who do not have a sufficient anticancer effect merely through administration of docetaxel alone and patients who have hormone resistance.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: July 13, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 11040074
    Abstract: Provided are vesicles derived from bacteria belonging to the genus Proteus and a use thereof. The inventors of the present invention experimentally confirmed that the vesicles was significantly reduced in samples of patients with cancers, allergic-respiratory diseases, cardiovascular diseases, metabolic diseases, or neuropsychiatric diseases, as compared to that of normal people, and the vesicles inhibited the secretion of inflammatory mediators due to pathogenic vesicles and also exhibited anticancer efficacy. Therefore, it is anticipated that the vesicles derived from bacteria belonging to the genus Proteus, according to the present invention, may be usefully used for the development of a method of diagnosing cancer, cardiovascular diseases, metabolic diseases, neuropsychiatric diseases, allergic-respiratory diseases, and inflammatory bowel diseases, and a composition for prevention, treatment, and/or alleviation.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: June 22, 2021
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Patent number: 11040071
    Abstract: The present invention offers a solution to the lack of an effective alternative method to those already known to treat angiogenesis. In particular, the present invention is the first to show that a substantially pure population of exosomes derived from MenSCs have capacity to reduce tumor angiogenesis in diseases such as prostate cancer, breast cancer and pancreatic cancer. In this sense, the present invention shows that a substantially pure population of MenSCs-derived exosomes reduce the endogenous levels of reactive oxygen species (ROS) in cancer cells and the expression of pro-angiogenic factors such as VEGF, NF-KB, FGF and HIF? in the treated tumors. Overall, the invention offers a promising alternative method to treat angiogenesis. Since it is principally composed of exosomes produced by the Stem cells present in menstrual fluid, the invention provides an ease access and repeated sampling in a non-invasive manner. Such attributes allow the rapid production of the treatment.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: June 22, 2021
    Assignee: Cells for Cells S.A.
    Inventors: Maroun Khoury, Francisca Alcayaga
  • Patent number: 11033610
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: June 15, 2021
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
  • Patent number: 11021692
    Abstract: Polynucleotides encoding hepatitis B virus (HBV) core antigen and polymerase antigen, and related combinations are described. Also described are vectors, such as DNA plasmids or viral vectors, expressing the HBV core and polymerase antigens, and immunogenic compositions containing the expression vectors. Methods of inducing an immune response against HBV or treating a HBV-induced disease, particularly in individuals having chronic HBV infection, using the immunogenic compositions are also described.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: June 1, 2021
    Inventors: Daniel Boden, Helen Horton, Jean-Marc Edmond Fernand Marie Neefs, Soumitra Roy, Dorien De Pooter
  • Patent number: 11020452
    Abstract: Compositions and methods for topical treatment of the hyperpigmented lesions of melasma are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied gel, lotion, wash, shampoo, cream, or mask. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 1, 2021
    Assignee: Medicell Technologies, LLC
    Inventor: Nikolay Turovets
  • Patent number: 11020476
    Abstract: Provided herein are Modified Vaccinia Ankara (MVA) vectors and adenovirus vectors encoding HBV antigens. Also provided are methods of enhancing an immune response in a human subject by utilizing the MVA and adenovirus vectors encoding HBV antigens in a prime/boost regimen to the enhance the immune response in the human subject.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: June 1, 2021
    Inventors: Daniel Boden, Helen Horton, Jean-Marc Edmond Fernand Marie Neefs, Soumitra Roy, Jerôme Hubertina Henricus Victor Custers, Roland Christian Zahn, Markus Kalla
  • Patent number: 11020473
    Abstract: The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5? copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5? copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 1, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MINISTÈRE DES ARMÉES—Direction Centrale du Service de Sante des Armée
    Inventors: Frederic Tangy, Anastassia Komarova, Marie Mura, Chantal Combredet
  • Patent number: 11016093
    Abstract: The present disclosure provides synthetic antibodies specific for a disease-associated antigen, and methods of using the antibodies in disease therapy. The present disclosure further provides diagnostic assays involving detecting the presence and/or level in biological sample of an antibody specific for a disease-associated antigen.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: May 25, 2021
    Assignee: The Regents of the University of California
    Inventors: Lawrence H. Fong, Serena Kwek MacPhee
  • Patent number: 11013797
    Abstract: A method for preventing or treating porcine epidemic diarrhea, the method including: administering a live vaccine of a porcine epidemic diarrhea virus and an adjuvant to a pig through oral administration or nasal administration; and administering an inactivated vaccine of the porcine epidemic diarrhea virus and an adjuvant to the pig through intramuscular administration.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 25, 2021
    Assignees: NIPPON INSTITUTE FOR BIOLOGICAL SCIENCE, NISSEIKEN CO., LTD.
    Inventors: Tetsuo Sato, Kazuki Oroku, Yoshiyuki Ohshima, Yoshiaki Furuya, Nobuyuki Tsutsumi
  • Patent number: 11000566
    Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: May 11, 2021
    Assignee: BIOINCEPT, LLC
    Inventor: Eytan R. Barnea
  • Patent number: 10995139
    Abstract: Described herein are interleukin-10 receptor-2 peptides, antibodies that bind the peptides, compositions including the peptides and antibodies and methods of use of the peptides and antibodies. The interleukin-10 receptor-2 peptide consists of an 8-15 amino acid sequence that includes SEQ ID NO: 1 ((I/V)P(P/K/V/E)P(E/K/R/Q)N(A/V)R), SEQ ID NO: 2 ((S/L/V)PAF(A/P)(K/Q)(G/T/E)(N/T/D)), or SEQ ID NO: 3 (PP(G/T/Q/V)(V/T/A)(R/H/T/S)(GN/NHP/SAA)).
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: May 4, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Maria K. Arendt, Mark E. Cook